Dr Reddy's Labs Q3 PAT likely at Rs 301 cr

Dr Reddy's Labs (DRL) is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax is expected to be at Rs 301 crore as against loss of Rs 521.7 crore on year-on-year basis, as per International Financial Reporting Standards (IFRS).

January 25, 2011 / 12:43 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Dr Reddy's Labs (DRL) is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax is expected to be at Rs 301 crore as against loss of Rs 521.7 crore on year-on-year basis, as per International Financial Reporting Standards (IFRS).

The company saw extraordinary outflow of Rs 860 crore in Q3FY10 on account of Betapharm.

Revenues are seen going up by 13.4% to Rs 1,960 crore from Rs 1,730 crore. Operating profit margin is seen improving at 19% versus 15.3%.

Q3FY10 adjusted PAT was at Rs 230 crore.

Watch out for:

-US boosted due to one off opportunity Zafirlukast (Accolate) and limited competition drug Lansoprazole (Prevacid), Tacrolimus (Prograf), Lotrel generic and scale up of Omeprazole OTC
-Accolate Generic is a small opportunity: Launched in November, USD 50 million drug, FTF
-Watch for Europe, in Q2 it declined 17% to Rs 236 cr with Betapharm revenues down 26%
-Compulsory price rebates of 16% to be given by co

first published: Jan 25, 2011 12:41 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.